RelB forms transcriptionally inactive complexes with RelA/p65

被引:130
作者
Marienfeld, R
May, MJ
Berberich, I
Serfling, E
Ghosh, S
Neumann, M
机构
[1] Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA
[3] Univ Wurzburg, Inst Virol & Immunobiol, D-97080 Wurzburg, Germany
[4] Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany
[5] Univ Magdeburg, Inst Expt Internal Med, D-39120 Magdeburg, Germany
关键词
D O I
10.1074/jbc.M301945200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RelB is an unusual member of the NF-kappaB transcription factor family that acts as both a transcriptional activator as well as a repressor of NF-kappaB-dependent gene expression. Although RelB promotes gene expression when it associates with p50/NF-kappaB1 or p52/NF-kappaB2, the precise molecular mechanisms through which it represses NF-kappaB remain unclear. To examine this inhibitory function in more detail, we employed reporter gene assays and found that RelB represses at the level of RelA. Furthermore, electrophoretic mobility shift analysis revealed that in vitro translated RelB impaired the DNA binding activity of RelA and that overexpressed RelB significantly reduced tumor necrosis factor-alpha-induced RelA activity in murine embryonic fibroblasts. Intriguingly, this inhibitory effect was due to the formation of RelA.RelB heterodimers that were unable to bind to kappaB sites in vitro strongly suggesting that these newly described NF-kappaB dimers cannot bind DNA. Expression pattern analysis revealed that RelA.RelB heterodimers appeared at relatively low levels in both lymphoid and non-lymphoid cells. However, the presence of these complexes increased following stimulation with phorbolesters or lipopolysaccharide or by overexpression of constitutively active IKKbeta. Functional characterization of RelA.RelB heterodimers in NIH3T3 murine embryonic fibroblasts revealed that they are not regulated by IkappaB proteins and are located in both the cytoplasm and the nucleus. Taken together, our findings demonstrate that sequestration of RelA in transcriptionally inactive RelA.RelB complexes provides a molecular mechanism that may explain the repressive role of RelB on NF-kappaB-dependent gene expression.
引用
收藏
页码:19852 / 19860
页数:9
相关论文
共 35 条
[1]  
BOURS V, 1994, ONCOGENE, V9, P1699
[2]   Transcription of the RelB gene is regulated by NF-κB [J].
Bren, GD ;
Solan, NJ ;
Miyoshi, H ;
Pennington, KN ;
Pobst, LJ ;
Paya, CV .
ONCOGENE, 2001, 20 (53) :7722-7733
[3]   A novel form of the RelA nuclear factor κB subunit is induced by and forms a complex with the proto-oncogene c-Myc [J].
Chapman, NR ;
Webster, GA ;
Gillespie, PJ ;
Wilson, BJ ;
Crouch, DH ;
Perkins, ND .
BIOCHEMICAL JOURNAL, 2002, 366 (02) :459-469
[4]   DIFFERENTIAL INTERACTIONS OF REL-NF-KAPPA-B COMPLEXES WITH I-KAPPA-B-ALPHA DETERMINE POOLS OF CONSTITUTIVE AND INDUCIBLE NF-KAPPA-B ACTIVITY [J].
DOBRZANSKI, P ;
RYSECK, RP ;
BRAVO, R .
EMBO JOURNAL, 1994, 13 (19) :4608-4616
[5]   Receptor-specific induction of NF-κB components in primary B cells [J].
Francis, DA ;
Sen, RJ ;
Rice, N ;
Rothstein, TL .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (03) :285-293
[6]   NF-κB and rel proteins:: Evolutionarily conserved mediators of immune responses [J].
Ghosh, S ;
May, MJ ;
Kopp, EB .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :225-260
[7]   Missing pieces in the NF-κB puzzle [J].
Ghosh, S ;
Karin, M .
CELL, 2002, 109 :S81-S96
[8]   p300/CBP-dependent and -independent transcriptional interference between NF-κB RelA and p53 [J].
Ikeda, A ;
Sun, XG ;
Li, Y ;
Zhang, YK ;
Eckner, R ;
Doi, TS ;
Takahashi, T ;
Obata, Y ;
Yoshioka, K ;
Yamamoto, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 272 (02) :375-379
[9]   RelB-p50 NF-κB complexes are selectively induced by cytomegalovirus immediate-early protein 1:: Differential regulation of Bcl-xL promoter activity by NF-κB family members [J].
Jiang, HY ;
Petrovas, C ;
Sonenshein, GE .
JOURNAL OF VIROLOGY, 2002, 76 (11) :5737-5747
[10]  
Kistler B, 1998, J IMMUNOL, V160, P2308